Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Gene Amplification”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Testing effectiveness (Phase 2)Looking for participantsNCT06343064
What this trial is testing

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT03539536
What this trial is testing

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AbbVie 270
Large-scale testing (Phase 3)Looking for participantsNCT07109531
What this trial is testing

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 286
Large-scale testing (Phase 3)Study completedNCT05015608
What this trial is testing

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Who this might be right for
Non-small Cell Lung Cancer
Hutchison Medipharma Limited 216
Testing effectiveness (Phase 2)UnknownNCT04338243
What this trial is testing

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Who this might be right for
Negative T790M Mutation and Met Amplification
Haihe Biopharma Co., Ltd. 70
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Looking for participantsNCT06116682
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357975
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 44
Large-scale testing (Phase 3)UnknownNCT06110663
What this trial is testing

HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 314
Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Testing effectiveness (Phase 2)Study completedNCT04084717
What this trial is testing

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Who this might be right for
Non-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene Rearrangement+2 more
University Health Network, Toronto 33
Testing effectiveness (Phase 2)WithdrawnNCT05567055
What this trial is testing

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Who this might be right for
Non-small Cell Lung Cancer
Timothy Burns, MD, PHD
Testing effectiveness (Phase 2)Study completedNCT02435121
What this trial is testing

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Who this might be right for
Neoplasm Malignant
Sanofi 1
Testing effectiveness (Phase 2)Study completedNCT02648724
What this trial is testing

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Who this might be right for
OncologyMET Gene AmplificationNSCLC+2 more
Symphogen A/S 57
Not applicableUnknownNCT02002416
What this trial is testing

Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma

Who this might be right for
Gastric Cancer
Sun Yat-sen University 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Study completedNCT02449551
What this trial is testing

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 16
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Next Page